|
2018-12-26 |
2018-12-24 |
V
Vente
|
Gurney Austin
See Remarks
Dirigeant
|
11 117
-14.3%
0,60
6 669 USD
|
11 117
-14.3%
|
0,60
|
6 669 USD
|
|
|
2018-10-11 |
2018-10-10 |
V
Vente
|
Li Yvonne
See Remarks
Dirigeant
|
927
-1.5%
2,02
1 873 USD
|
927
-1.5%
|
2,02
|
1 873 USD
|
|
|
2018-10-11 |
2018-10-10 |
V
Vente
|
Stagg Robert
SVP, Clinical R&D
Dirigeant
|
927
-2.2%
2,01
1 863 USD
|
927
-2.2%
|
2,01
|
1 863 USD
|
|
|
2018-10-11 |
2018-10-10 |
V
Vente
|
Lewicki John A.
President & CEO
Administrateur exécutif
|
1 156
-2.0%
2,01
2 324 USD
|
1 156
-2.0%
|
2,01
|
2 324 USD
|
|
|
2018-10-11 |
2018-10-10 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
Dirigeant
|
1 156
-2.2%
2,02
2 335 USD
|
1 156
-2.2%
|
2,02
|
2 335 USD
|
|
|
2018-10-11 |
2018-10-10 |
V
Vente
|
Gurney Austin
See Remarks
Dirigeant
|
1 156
-1.5%
2,01
2 324 USD
|
1 156
-1.5%
|
2,01
|
2 324 USD
|
|
|
2018-10-10 |
2018-10-09 |
V
Vente
|
Stagg Robert
SVP, Clinical R&D
Dirigeant
|
1 686
-3.9%
2,13
3 589 USD
|
1 686
-3.9%
|
2,13
|
3 589 USD
|
|
|
2018-10-10 |
2018-10-09 |
VP
Vente planifiée
|
Li Yvonne
See Remarks
Dirigeant
|
1 229
-2.0%
2,13
2 616 USD
|
1 229
-2.0%
|
2,13
|
2 616 USD
|
|
|
2018-10-10 |
2018-10-09 |
VP
Vente planifiée
|
Gurney Austin
See Remarks
Dirigeant
|
1 686
-2.1%
2,13
3 589 USD
|
1 686
-2.1%
|
2,13
|
3 589 USD
|
|
|
2018-10-10 |
2018-10-09 |
VP
Vente planifiée
|
Lewicki John A.
President & CEO
Administrateur exécutif
|
2 296
-3.9%
2,13
4 888 USD
|
2 296
-3.9%
|
2,13
|
4 888 USD
|
|
|
2018-10-10 |
2018-10-09 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
Dirigeant
|
1 686
-3.1%
2,13
3 589 USD
|
1 686
-3.1%
|
2,13
|
3 589 USD
|
|
|
2018-04-26 |
2018-04-24 |
V
Vente
|
Stagg Robert
SVP, Clinical R&D
|
4 051
-8.6%
2,68
10 848 USD
|
4 051
-8.6%
|
2,68
|
10 848 USD
|
|
|
2018-04-26 |
2018-04-24 |
V
Vente
|
Lewicki John A.
President & CEO
Administrateur exécutif
|
4 557
-7.6%
2,68
12 202 USD
|
4 557
-7.6%
|
2,68
|
12 202 USD
|
|
|
2018-04-26 |
2018-04-24 |
V
Vente
|
Gurney Austin
See Remarks
|
4 051
-5.0%
2,68
10 848 USD
|
4 051
-5.0%
|
2,68
|
10 848 USD
|
|
|
2018-04-26 |
2018-04-24 |
V
Vente
|
Li Yvonne
See Remarks
|
5 062
-7.8%
2,68
13 555 USD
|
5 062
-7.8%
|
2,68
|
13 555 USD
|
|
|
2018-04-26 |
2018-04-24 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
|
4 051
-6.9%
2,68
10 848 USD
|
4 051
-6.9%
|
2,68
|
10 848 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
|
1 202
-2.0%
4,24
5 099 USD
|
1 202
-2.0%
|
4,24
|
5 099 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
|
46
-0.1%
4,26
196 USD
|
46
-0.1%
|
4,26
|
196 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Patel Sunil
See Remarks
|
1 202
-1.7%
4,24
5 099 USD
|
1 202
-1.7%
|
4,24
|
5 099 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Patel Sunil
See Remarks
|
46
-0.1%
4,27
196 USD
|
46
-0.1%
|
4,27
|
196 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
HASTINGS PAUL J
Chairman & CEO
|
1 346
-1.7%
4,24
5 709 USD
|
1 346
-1.7%
|
4,24
|
5 709 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
HASTINGS PAUL J
Chairman & CEO
|
52
-0.1%
4,26
222 USD
|
52
-0.1%
|
4,26
|
222 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Gurney Austin
See Remarks
|
1 202
-1.5%
4,24
5 099 USD
|
1 202
-1.5%
|
4,24
|
5 099 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Gurney Austin
See Remarks
|
46
-0.1%
4,27
196 USD
|
46
-0.1%
|
4,27
|
196 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Lewicki John A.
EVP, Research & Development
|
1 202
-1.7%
4,24
5 099 USD
|
1 202
-1.7%
|
4,24
|
5 099 USD
|
|
|
2017-10-12 |
2017-10-10 |
V
Vente
|
Lewicki John A.
EVP, Research & Development
|
46
-0.1%
4,26
196 USD
|
46
-0.1%
|
4,26
|
196 USD
|
|
|
2017-06-07 |
2017-06-05 |
A
Achat
|
KARSEN PERRY A
|
10 000
+inf%
3,46
34 588 USD
|
10 000
+inf%
|
3,46
|
34 588 USD
|
|
|
2017-05-26 |
2017-05-26 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
3 222
-100.0%
3,70
11 927 USD
|
3 222
-100.0%
|
3,70
|
11 927 USD
|
|
|
2017-05-26 |
2017-05-26 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
6 358
-100.0%
3,70
23 536 USD
|
6 358
-100.0%
|
3,70
|
23 536 USD
|
|
|
2017-05-26 |
2017-05-25 |
A
Achat
|
LASERSOHN JACK W
Administrateur non-exécutif
|
34 614
+22.9%
3,37
116 639 USD
|
34 614
+22.9%
|
3,37
|
116 639 USD
|
|
|
2017-05-26 |
2017-05-24 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
1 447
-31.0%
3,72
5 377 USD
|
1 447
-31.0%
|
3,72
|
5 377 USD
|
|
|
2017-05-26 |
2017-05-24 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
2 853
-31.0%
3,72
10 601 USD
|
2 853
-31.0%
|
3,72
|
10 601 USD
|
|
|
2017-05-25 |
2017-05-23 |
A
Achat
|
LASERSOHN JACK W
Administrateur non-exécutif
|
20 000
+15.3%
3,55
71 000 USD
|
20 000
+15.3%
|
3,55
|
71 000 USD
|
|
|
2017-05-22 |
2017-05-19 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
2 519
-35.0%
3,70
9 324 USD
|
2 519
-35.0%
|
3,70
|
9 324 USD
|
|
|
2017-05-22 |
2017-05-19 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
4 968
-35.0%
3,70
18 388 USD
|
4 968
-35.0%
|
3,70
|
18 388 USD
|
|
|
2017-05-18 |
2017-05-16 |
A
Achat
|
LASERSOHN JACK W
Administrateur non-exécutif
|
23 507
+21.8%
3,49
82 061 USD
|
23 507
+21.8%
|
3,49
|
82 061 USD
|
|
|
2017-05-18 |
2017-05-16 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
2 321
-24.4%
3,58
8 313 USD
|
2 321
-24.4%
|
3,58
|
8 313 USD
|
|
|
2017-05-18 |
2017-05-16 |
V
Vente
|
ROOT JONATHAN D
Administrateur non-exécutif
|
4 579
-24.4%
3,58
16 401 USD
|
4 579
-24.4%
|
3,58
|
16 401 USD
|
|
|
2017-04-05 |
2017-04-04 |
V
Vente
|
Patel Sunil
See Remarks
|
5 711
-18.9%
9,06
51 731 USD
|
5 711
-18.9%
|
9,06
|
51 731 USD
|
|
|
2017-04-05 |
2017-04-04 |
V
Vente
|
Patel Sunil
See Remarks
|
43
-0.1%
8,87
382 USD
|
43
-0.1%
|
8,87
|
382 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
5 711
-9.1%
9,06
51 731 USD
|
5 711
-9.1%
|
9,06
|
51 731 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
43
-0.1%
8,87
381 USD
|
43
-0.1%
|
8,87
|
381 USD
|
|
|
2017-04-05 |
2017-04-04 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
|
4 284
-16.6%
9,06
38 805 USD
|
4 284
-16.6%
|
9,06
|
38 805 USD
|
|
|
2017-04-05 |
2017-04-04 |
V
Vente
|
Hager Alicia J.
SVP & General Counsel
|
32
-0.1%
8,87
284 USD
|
32
-0.1%
|
8,87
|
284 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
6 425
-16.5%
9,06
58 199 USD
|
6 425
-16.5%
|
9,06
|
58 199 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
48
-0.1%
8,87
426 USD
|
48
-0.1%
|
8,87
|
426 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Gurney Austin
See Remarks
|
5 711
-11.7%
9,06
51 731 USD
|
5 711
-11.7%
|
9,06
|
51 731 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Gurney Austin
See Remarks
|
43
-0.1%
8,87
381 USD
|
43
-0.1%
|
8,87
|
381 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Lewicki John A.
EVP, Research & Development
|
5 711
-19.9%
9,06
51 731 USD
|
5 711
-19.9%
|
9,06
|
51 731 USD
|
|
|
2017-04-05 |
2017-04-04 |
VP
Vente planifiée
|
Lewicki John A.
EVP, Research & Development
|
43
-0.1%
8,87
381 USD
|
43
-0.1%
|
8,87
|
381 USD
|
|
|
2017-03-17 |
2017-03-15 |
VP
Vente planifiée
|
Hager Alicia J.
SVP & General Counsel
|
6 652
-20.4%
10,00
66 520 USD
|
6 652
-20.4%
|
10,00
|
66 520 USD
|
|
|
2017-01-09 |
2017-01-06 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
21 369
-36.4%
8,52
181 957 USD
|
21 369
-36.4%
|
8,52
|
181 957 USD
|
|
|
2017-01-09 |
2017-01-05 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
21 369
-36.4%
8,17
174 602 USD
|
21 369
-36.4%
|
8,17
|
174 602 USD
|
|
|
2017-01-05 |
2017-01-03 |
VP
Vente planifiée
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
12 763
-17.3%
7,64
97 448 USD
|
12 763
-17.3%
|
7,64
|
97 448 USD
|
|
|
2017-01-05 |
2017-01-03 |
VP
Vente planifiée
|
Lewicki John A.
EVP, Research & Development
|
9 175
-22.5%
7,63
70 045 USD
|
9 175
-22.5%
|
7,63
|
70 045 USD
|
|
|
2016-11-18 |
2016-11-16 |
VP
Vente planifiée
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
Dirigeant
|
12 500
-17.0%
9,89
123 609 USD
|
12 500
-17.0%
|
9,89
|
123 609 USD
|
|
|
2016-01-12 |
2016-01-11 |
VP
Vente planifiée
|
Dupont Jakob
SVP & Chief Medical Officer
Dirigeant
|
2 500
-10.8%
20,01
50 021 USD
|
2 500
-10.8%
|
20,01
|
50 021 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Patel Sunil
See Remarks
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Lewicki John A.
EVP & Chief Scientific Officer
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Dupont Jakob
SVP & Chief Medical Officer
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Hoey Timothy
SVP, Cancer Biology
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Gurney Austin
See Remarks
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-07 |
V
Vente
|
Hager Alicia J.
VP & General Counsel
Dirigeant
|
1
-0.0%
21,33
21 USD
|
1
-0.0%
|
21,33
|
21 USD
|
|
|
2016-01-08 |
2016-01-06 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
77
-0.3%
21,54
1 659 USD
|
77
-0.3%
|
21,54
|
1 659 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Patel Sunil
See Remarks
Dirigeant
|
69
-0.4%
21,65
1 494 USD
|
69
-0.4%
|
21,65
|
1 494 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Lewicki John A.
EVP & Chief Scientific Officer
Dirigeant
|
69
-0.4%
21,56
1 488 USD
|
69
-0.4%
|
21,56
|
1 488 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Dupont Jakob
SVP & Chief Medical Officer
Dirigeant
|
69
-0.3%
21,54
1 486 USD
|
69
-0.3%
|
21,54
|
1 486 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Hoey Timothy
SVP, Cancer Biology
Dirigeant
|
69
-0.1%
21,56
1 488 USD
|
69
-0.1%
|
21,56
|
1 488 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Gurney Austin
See Remarks
Dirigeant
|
69
-0.2%
21,54
1 486 USD
|
69
-0.2%
|
21,54
|
1 486 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Hager Alicia J.
VP & General Counsel
Dirigeant
|
52
-0.4%
21,54
1 120 USD
|
52
-0.4%
|
21,54
|
1 120 USD
|
|
|
2016-01-08 |
2016-01-06 |
VP
Vente planifiée
|
HASTINGS PAUL J
Chairman & CEO
Administrateur exécutif
|
2 335
-9.6%
22,30
52 072 USD
|
2 335
-9.6%
|
22,30
|
52 072 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Patel Sunil
See Remarks
Dirigeant
|
2 092
-10.5%
22,30
46 653 USD
|
2 092
-10.5%
|
22,30
|
46 653 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Lewicki John A.
EVP & Chief Scientific Officer
Dirigeant
|
2 092
-10.5%
22,30
46 653 USD
|
2 092
-10.5%
|
22,30
|
46 653 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Dupont Jakob
SVP & Chief Medical Officer
Dirigeant
|
2 092
-9.2%
22,30
46 653 USD
|
2 092
-9.2%
|
22,30
|
46 653 USD
|
|
|
2016-01-08 |
2016-01-06 |
V
Vente
|
Hoey Timothy
SVP, Cancer Biology
Dirigeant
|
2 092
-4.2%
22,30
46 653 USD
|
2 092
-4.2%
|
22,30
|
46 653 USD
|
|
